Consultation on proposed 2021/22 Invitation to Tender: For suppliers
Te Pātaka Whaioranga, Pharmac, is seeking feedback from pharmaceutical suppliers and interested parties on the proposed 2021/22 Invitation to Tender (ITT)
Pharmac is seeking feedback from pharmaceutical suppliers and interested parties on:
- A proposal to tender certain pharmaceuticals for principal supply;
- The implications of awarding Principal Supply Status; and
- Commercial proposals as an alternative to tendering.
Pharmac welcomes all feedback on the draft 2021/22 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the Pharmac Board (or its Delegate, where applicable) prior to making a decision on this proposal.
Download a PDF version of this consultation
- Consultation document - suppliers pdf [PDF 184 KB]
Feedback should be submitted by the following dates; late feedback may not be considered:
Alternative commercial proposal responses due by:
4 pm (New Zealand Time), Wednesday 11 August 2021
All other consultation responses due by:
4 pm (New Zealand Time), Monday 16 August 2021
Feedback should be provided by submitting an email to the Tender Analysts:
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.
Details of the proposed 2021/22 Tender
In general, the proposed 2021/22 Tender process would be similar to the 2020/21 Tender in that the 2021/22 Tender would result in awarding Principal Supply Status (PSS) (previously Sole Supply Status and/or Hospital Supply Status).
We have historically indicated a preference for the pack size of Tender Items supplied in the community to be either a 30-day or 90-day pack, as this improves dispensing efficiency and reduces wastage. In the coming years we are intending to put greater emphasis on the appropriateness of both packaging type and pack size, with a preference for bottle packs for tablets and capsules where possible. In this Tender we have identified specific packaging preferences for individual products in Schedule 2, and we expect to expand this to a much wider range of products in future Tenders.
We are seeking feedback on the composition of the draft 2021/22 Tender. This is still under development and may change before it is taken to the Board (or its Delegate) for approval and subsequently issued. At this stage, but depending on the extent of any changes, Pharmac does not intend to send out further drafts for consultation.
In addition to Alternative Commercial Proposals (discussed below), we seek comments on all sections of the draft 2021/22 Tender, in particular on:
- An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft 2021/22 Tender, that you consider should be tendered, and the reasons for that view. If you wish, you may provide a non-binding confidential indication of the price or price range that you might be able to offer for a line item or group of line items you wish to have tendered;
- An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft 2021/22 Tender, that you consider would be inappropriate to tender, and the reasons for that view, including any contractual constraints or patent protection that could restrict Pharmac from awarding a tender on a particular pharmaceutical;
- Your views on whether any product included in Schedule Two might have more than 5% of patients needing to access an alternative brand;
- Feedback on any unresolved Tender Bid(s) from previous tenders that you consider should remain open for acceptance. Please note that some currently unresolved Tender Bids may be resolved prior to the consultation deadline and the final 2021/22 Tender being issued.
Draft Invitation to Tender
A complete copy of the draft 2021/22 Tender, including the proposed terms and conditions which successful tender bids would be subject to, is available on our website.
The draft 2021/22 Tender comprises the following sections:
Schedule 1: Definitions and interpretation
Schedule 2: The list of pharmaceuticals proposed for tender* #
Schedule 3: The tender process (for both hospital and community tender bids)
Schedule 4: Contract terms for Principal Supply Status for both community and hospital supply
Schedule 5: Additional contract terms for Principal Supply Status for community supply
Schedule 6: Additional contract terms for Principal Supply Status for hospital supply
Schedule 7: Additional special terms for particular pharmaceuticals
*The units provided in Schedule Two consist of market data for the year ended 30 June 2021. The figures included are indicative only and are provided on the basis set out in clause 1.3 of Schedule 2 of the draft 2021/22 Tender.
#The final list of products, which may change following consultation, would be released as part of the 2021/22 Tender, following Board (or its Delegate) approval. You may provide feedback on the inclusion of any additional pharmaceuticals after the 2021/22 Tender has been issued, and any such feedback would be considered by the Board (or its Delegate) before making a final decision on any product, provided that any feedback is given prior to the tender close date in late 2021.
Key proposed inclusions:
Summary of change
Schedule and clause references in the draft 2021/22 ITT
Further clarification with additional/amended definitions
Brand Allowance Pharmaceutical
Tender Submission Form
Total Brand Allowance Pharmaceutical Volume
Ability to extend supply arrangements either to the community market or hospital market where a Tender Bid was received for the alternative market.
Schedule 3 clauses 1.4 and 1.5
Clarification that only Tender Bids that have been entered and submitted via the electronic form are considering conforming Tender Bids (i.e. Tender Bids submitted bypassing the data entry format would not be considered Conforming).
Schedule 3 clause 6 (ii)
Schedule 4 clause 1.5
Additions to the arrangements after the End Date.
Schedule 5 clause 1.5 (iii), and Schedule 6 clause 1.3 (iv)
Warranty the price is inclusive of all costs relating to the Tender Item.
Schedule 5 clause 3.3
Clarification to price and volume data access.
Schedule 6 clause 10 (c)
Additional Special Terms
Intra-uterine copper devices
Additional Special Terms have been included in the draft 2021/22 Tender contract for intra-uterine copper devices (Schedule Seven). This clause requires any potential suppliers to offer education, training and support resources to patients and healthcare professionals. This clause also outlines the additional information suppliers must provide relating to their Tender Bid. The full Additional Special Terms for intra-uterine copper devices can be found in the draft 2021/22 Tender contract on the Pharmac website.
Long-acting filgrastim has been included in the draft 2021/22 Tender. Pharmac would consider bids for any long-acting filgrastim product (e.g. pegfilgrastim, pegfilgrastim biosimilars, and lipegfilgrastim) for this market; all of which would be subject to the same access criteria. Pharmac reserves the right to award the tender to one long-acting filgrastim product for the entire market.
Please note: in response to feedback from the Ministry of Health Haematology Working Group (HWG) during the early stages of the COVID-19 pandemic in 2020, Pharmac amended the access criteria for pegfilgrastim. Access was widened to patients when used for the prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5% [was previously 20%]). This change was intended to be a temporary health sector resource saving measure with the intention that access criteria would revert to the previous threshold of 20% on 1 December 2020.
A decision on whether to revert to the 20% threshold was deferred in August 2020(external link). A decision on whether to maintain or amend the access criteria is expected to be made over the coming mont